Portuguese 
English 
Spanish 
5 min of reading 
0 comments 
McGill researchers have for the first time identified the brain cells that function abnormally in depression, including excitatory neurons and microglia, a discovery published in Nature Genetics that could transform the treatment of the disease affecting 264 million people worldwide.
Scientists at McGill and the Douglas Institute in Canada have for the first time managed to locate the brain cells that behave differently in people diagnosed with depression, an advance that transforms the understanding of a disease debated for decades between the emotional and biological fields. The study, published in Nature Genetics, used single-cell genomic analysis techniques to investigate genetic material from thousands of individual cells extracted from donated brain tissue, comparing material from individuals diagnosed with depression and healthy people. The result revealed that two specific groups of cells show altered functioning in the brains of depressive patients: excitatory neurons, involved in emotional regulation and responses to stress situations, and a subtype of microglia, which are the brain’s defense cells responsible for controlling inflammatory processes.
The identification of these cells changes the landscape for a fundamental reason. Until now, treatments for depression operated without knowing exactly which cellular structures were failing, meaning that medications and therapies acted generically on the entire nervous system instead of targeting the specific points where the problem originates. With the precise location of the defective cell groups, science gains for the first time a concrete target for developing targeted therapies, potentially more effective and with fewer side effects than the conventional antidepressants that have dominated the market for decades.
What researchers found inside the cells of brains with depression
The Canadian team did not analyze the brain as a single block. The single-cell genomics technique allowed researchers to isolate thousands of cells individually and examine how genes are expressed and which epigenetic mechanisms regulate the genetic code in each of them. By comparing cells from healthy people with those from individuals diagnosed with depression, scientists identified that two cell types showed clearly distinct functioning patterns in sick patients.
-
Scientists use plasma technology to convert methane into clean fuel with high efficiency and low energy cost.
-
Vale brings future mining with AI, autonomous trucks, circularity, and experience in the Amazon to the world’s largest industrial fair to turn the tide on its image and the energy transition.
-
Thwaites and Pine Island could be the trigger of a global coastal crisis: the two most dangerous glaciers on the planet, giants of Antarctica, are already vulnerable to current warming and could initiate a chain collapse capable of raising sea levels by at least 1 meter.
-
New Redmi Note 17 Pro Max leaked with a battery so large that it had to be reduced to comply with European regulations, and even so, the global version still delivers more battery life than any rival.
The first group are excitatory neurons, cells responsible for transmitting signals that activate other brain regions. In patients with depression, these neurons showed alterations in how their genes were expressed, disturbances that directly affect circuits linked to emotional regulation and the ability to cope with stress situations. The second group is a specific subtype of microglia, cells that function as the brain’s immune system. In depressive individuals, these defense cells exhibited abnormal behavior in controlling inflammation, a discovery that reinforces a line of research that had been gaining traction: that chronic inflammatory processes in the brain may be a central, rather than secondary, component of depression.
Why the discovery of these cells changes the debate about depression
For decades, part of society and even segments of the medical community treated depression as a predominantly psychological or emotional condition, minimizing its biological basis. The identification by the McGill team of specific brain cells that operate defectively in depressive patients provides concrete evidence that the disease has a cellular and genetic root, an argument that diminishes the claims of those who still doubt the legitimacy of the diagnosis or suggest that patients could simply “overcome” the condition with willpower. Depression is not a choice, and now the cells that prove it have a name, type, and location.
The impact goes beyond diagnosis validation. Understanding that excitatory neurons and microglia are the points of failure allows future research to focus resources on understanding why these specific cells malfunction in some individuals and not in others. If genetic factors, environmental factors, or combinations of both are responsible for dysregulating these two cell groups, the answer to this question could pave the way for prevention, not just treatment, transforming the approach to depression from reactive to proactive.
What the discovery reveals about current treatments for depression
The most widely prescribed antidepressants in the world primarily act on neurotransmitters such as serotonin, noradrenaline, and dopamine, modulating chemical communication between neurons broadly and indiscriminately. The McGill study reveals that this method is equivalent to medicating the entire brain when the problem is localized in specific cell groups, an approach that explains both the partial effectiveness of current medications and the side effects that lead many patients to abandon treatment. If the defective cells are excitatory neurons and microglia, drugs that act on the serotonergic system may be correcting consequences rather than causes.
For the researchers, the next step is to investigate how changes in these cells impact overall brain function. The stated goal is to determine whether therapies specifically designed to act on compromised excitatory neurons and dysfunctional microglia can offer superior results to currently available methods. A medication that directly targeted the cells identified by the study could, in theory, treat depression with greater precision, fewer adverse effects, and a higher success rate than generic antidepressants, a prospect that depends on clinical trials that will still take years but now have a starting point that did not exist before.
What it means for the 264 million people living with depression
The scale of the disease makes any advance in understanding its causes globally relevant. Around 264 million people worldwide live with depression according to World Health Organization estimates, and the condition is among the leading causes of disability on the planet, generating costs ranging from medical treatments and work absences to the immeasurable impact on families and personal relationships. For this population, the identification of the cells responsible for the disease represents the promise that treatment can evolve from trial and error to precision intervention.
The transition will not be immediate. Discovering which cells are failing is the first chapter of a process that includes understanding the molecular mechanisms behind the failure, developing compounds that selectively act on them, testing safety and efficacy in clinical trials, and only then making new medications available to the public. This path could take a decade or more, but the difference from everything that came before is that now science knows where to look. The researchers at McGill and the Douglas Institute have delivered the map, and what medicine does with it will determine whether depression continues to be treated in the dark or finally gets a therapy that hits the target.
And you, did you believe that depression had a proven biological cause or did you think it was more emotional? Does this discovery change your view on the disease? Leave your opinion in the comments.
Be the first to react!